Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Senkus, Elżbieta; Kyriakides, S.; Penault‐Llorca, Frédérique; Poortmans, Philip; Thompson, Alastair; Zackrisson, Sophia; Cardoso, Fátima

doi:10.1093/annonc/mdt284

Cited by 558 publications

(542 citation statements)

References 101 publications

Supporting

Mentioning

499

Contrasting

Unclassified

Order By: Relevance

“…One of the strongest predictors of long-term prognosis in primary breast cancer is the regional lymph node status [2]. Sentinel lymph-node (SLN) biopsy is currently preferred over axillary dissection as the standard of care for axillary staging in early, clinically node-negative breast cancer [3].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Sentinel Lymph Node Intraoperative Touch Imprint Cytology in Breast Cancer Surgery

Iacuzzo¹,

Troian²,

Bonadio³

et al. 2017

J Mol Biomark Diagn

View full text Add to dashboard Cite

Background: One of the strongest prognostic factor for breast cancer is the regional lymph node status, which can be evaluated intraoperatively by sentinel lymph node biopsy. Many methods (e.g. frozen section, touch imprint cytology (TIC) and one-step nucleic-acid amplification) are available to detect metastatic cells in axillary lymph nodes. The aim of this study is to evaluate the feasibility of using TIC to detect metastatic cells in sentinel lymph nodes.

show abstract

Section: Introductionmentioning

confidence: 99%

Evaluation of Sentinel Lymph Node Intraoperative Touch Imprint Cytology in Breast Cancer Surgery

Iacuzzo¹,

Troian²,

Bonadio³

et al. 2017

J Mol Biomark Diagn

View full text Add to dashboard Cite

show abstract

“…The European Society of Medical Oncology suggests the use of gene expression profiles to gain additional prognostic and/or predictive information to complement pathology assessment, particularly in patients with estrogen receptor (ER)-positive (+) breast cancer. 6 The current Dutch national (NABON) guideline for breast cancer (2012) recommends the use of a validated gene expression profile in patients with an invasive ductal carcinoma with ER-positive disease and a questionable indication for adjuvant chemotherapy (CT) based on conventional prognostic factors. 7 To date, research of gene expression profiles mainly focuses on the value of the test for the individual patient.…”

Section: Introductionmentioning

confidence: 99%

Using a gene expression signature when controversy exists regarding the indication for adjuvant systemic treatment reduces the proportion of patients receiving adjuvant chemotherapy: a nationwide study

Kuijer

Bommel

Drukker

et al. 2016

Genetics in Medicine

View full text Add to dashboard Cite

Methods:Patients within a national guideline directed indication area for 70-GS use who were surgically treated between November 2011 and April 2013 were selected from the Netherlands Cancer Registry database. The effect of 70-GS use on the administration of CT was evaluated in guideline-and age-delineated subgroups addressing potential effect of bias by linear mixed-effect modeling and instrumental variable (IV) analyses.Results: A total of 2,043 patients within the indicated area for 70-GS use were included, of whom 298 received a 70-GS. Without use of the 70-GS, 45% of patients received CT. The 70-GS use was associated with a 9.5% decrease in CT administration (95% confidence interval (CI): −15.7 to −3.3%) in linear mixed-effect model analyses and IV analyses showed similar results (−9.9%; 95% CI: −19.3 to −0.4). Conclusion:In patients in whom the Dutch national guidelines suggest the use of a gene-expression profile, 70-GS use is associated with a 10% decrease in the administration of adjuvant CT. Genet Med advance online publication 19 November 2015

show abstract

“…[63] и European Society for Medical Oncology (ESMO) 2015 г. [64] нет выделенных положений по лечению изолированного РП соска. Рекомендуется проводить лечение согласно стадии заболевания и морфологическому типу опухо-ли, а мастэктомию считать стандартом хирургическо-го лечения.…”

Section: опухоли женской репродуктивной системы Tumors Of Female Reprunclassified

Paget’s disease of the breast (a review of literature)

Никитина¹,

Нечушкин²,

Trigolosov³

et al. 2016

Tumors of female reproductive system

View full text Add to dashboard Cite

show abstract

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Cited by 558 publications

References 101 publications

Evaluation of Sentinel Lymph Node Intraoperative Touch Imprint Cytology in Breast Cancer Surgery

Evaluation of Sentinel Lymph Node Intraoperative Touch Imprint Cytology in Breast Cancer Surgery

Using a gene expression signature when controversy exists regarding the indication for adjuvant systemic treatment reduces the proportion of patients receiving adjuvant chemotherapy: a nationwide study

Paget’s disease of the breast (a review of literature)

Contact Info

Product

Resources

About